BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

504 related articles for article (PubMed ID: 17035872)

  • 1. Contrast-induced nephropathy in patients with chronic kidney disease undergoing computed tomography: a double-blind comparison of iodixanol and iopamidol.
    Barrett BJ; Katzberg RW; Thomsen HS; Chen N; Sahani D; Soulez G; Heiken JP; Lepanto L; Ni ZH; Ni ZH; Nelson R
    Invest Radiol; 2006 Nov; 41(11):815-21. PubMed ID: 17035872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The ACTIVE Trial: comparison of the effects on renal function of iomeprol-400 and iodixanol-320 in patients with chronic kidney disease undergoing abdominal computed tomography.
    Thomsen HS; Morcos SK; Erley CM; Grazioli L; Bonomo L; Ni Z; Romano L;
    Invest Radiol; 2008 Mar; 43(3):170-8. PubMed ID: 18301313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiac Angiography in Renally Impaired Patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease.
    Solomon RJ; Natarajan MK; Doucet S; Sharma SK; Staniloae CS; Katholi RE; Gelormini JL; Labinaz M; Moreyra AE;
    Circulation; 2007 Jun; 115(25):3189-96. PubMed ID: 17562951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of the efficacy and safety of iopamidol-370 and iodixanol-320 in patients undergoing multidetector-row computed tomography.
    Sahani DV; Soulez G; Chen KM; Lepanto L; Xu JR; Nelson RC; Grazioli L; Vanzulli A; Heiken JP;
    Invest Radiol; 2007 Dec; 42(12):856-61. PubMed ID: 18007158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The PREDICT study: a randomized double-blind comparison of contrast-induced nephropathy after low- or isoosmolar contrast agent exposure.
    Kuhn MJ; Chen N; Sahani DV; Reimer D; van Beek EJ; Heiken JP; So GJ
    AJR Am J Roentgenol; 2008 Jul; 191(1):151-7. PubMed ID: 18562739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of contrast-induced nephrotoxicity of iodixanol and iopromide in patients with renal insufficiency undergoing coronary angiography.
    Shin DH; Choi DJ; Youn TJ; Yoon CH; Suh JW; Kim KI; Cho YS; Cho GY; Chae IH; Kim CH
    Am J Cardiol; 2011 Jul; 108(2):189-94. PubMed ID: 21545991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nephrotoxicity of iodixanol versus iopamidol in patients undergoing peripheral angiography with or without endovascular therapy.
    Xiong HL; Peng M; Jiang XJ; Dong H; Che WQ; Chen Y; Zou YB; Xu B; Yang YJ; Gao RL
    Int Urol Nephrol; 2018 Oct; 50(10):1879-1886. PubMed ID: 29948863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of patient comfort between iodixanol and iopamidol in contrast-enhanced computed tomography of the abdomen and pelvis: a randomized trial.
    Weiland FL; Marti-Bonmati L; Lim L; Becker HC
    Acta Radiol; 2014 Jul; 55(6):715-24. PubMed ID: 24060817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nephrotoxicity of iodixanol versus iopamidol in patients with chronic kidney disease and diabetes mellitus undergoing coronary angiographic procedures.
    Laskey W; Aspelin P; Davidson C; Rudnick M; Aubry P; Kumar S; Gietzen F; Wiemer M;
    Am Heart J; 2009 Nov; 158(5):822-828.e3. PubMed ID: 19853704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of contrast-medium-induced nephropathy in high-risk patients undergoing MDCT--a pooled analysis of two randomized trials.
    Thomsen HS; Morcos SK
    Eur Radiol; 2009 Apr; 19(4):891-7. PubMed ID: 19002467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal effects of contrast media in diabetic patients undergoing diagnostic or interventional coronary angiography.
    Hardiek KJ; Katholi RE; Robbs RS; Katholi CE
    J Diabetes Complications; 2008; 22(3):171-7. PubMed ID: 18413220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal toxicity evaluation and comparison between visipaque (iodixanol) and hexabrix (ioxaglate) in patients with renal insufficiency undergoing coronary angiography: the RECOVER study: a randomized controlled trial.
    Jo SH; Youn TJ; Koo BK; Park JS; Kang HJ; Cho YS; Chung WY; Joo GW; Chae IH; Choi DJ; Oh BH; Lee MM; Park YB; Kim HS
    J Am Coll Cardiol; 2006 Sep; 48(5):924-30. PubMed ID: 16949481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Iodixanol: risk of subsequent contrast nephropathy in cancer patients with underlying renal insufficiency undergoing diagnostic computed tomography examinations.
    Cheruvu B; Henning K; Mulligan J; Klippenstein D; Lawrence D; Gurtoo L; Gottlieb RH
    J Comput Assist Tomogr; 2007; 31(4):493-8. PubMed ID: 17882021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N-Acetylcysteine added to volume expansion with sodium bicarbonate does not further prevent contrast-induced nephropathy: results from the cardiac angiography in renally impaired patients study.
    Staniloae CS; Doucet S; Sharma SK; Katholi RE; Mody KR; Coppola JT; Solomon R
    J Interv Cardiol; 2009 Jun; 22(3):261-5. PubMed ID: 19490358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nephrotoxic effects of iodixanol and iopromide in patients with abnormal renal function receiving N-acetylcysteine and hydration before coronary angiography and intervention: a randomized trial.
    Juergens CP; Winter JP; Nguyen-Do P; Lo S; French JK; Hallani H; Fernandes C; Jepson N; Leung DY
    Intern Med J; 2009 Jan; 39(1):25-31. PubMed ID: 18771430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iso-osmolality versus low-osmolality iodinated contrast medium at intravenous contrast-enhanced CT: effect on kidney function.
    Nguyen SA; Suranyi P; Ravenel JG; Randall PK; Romano PB; Strom KA; Costello P; Schoepf UJ
    Radiology; 2008 Jul; 248(1):97-105. PubMed ID: 18483232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative investigation of i.v. iohexol and iopamidol: effect on renal function in low-risk outpatients undergoing CT.
    Dillman JR; al-Hawary M; Ellis JH; Cohan RH; Kaza R; Myles JD; Khalatbari S; Francis IR
    AJR Am J Roentgenol; 2012 Feb; 198(2):392-7. PubMed ID: 22268183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective, double-blind, randomized, controlled trial on the efficacy and cardiorenal safety of iodixanol vs. iopromide in patients with chronic kidney disease undergoing coronary angiography with or without percutaneous coronary intervention.
    Nie B; Cheng WJ; Li YF; Cao Z; Yang Q; Zhao YX; Guo YH; Zhou YJ
    Catheter Cardiovasc Interv; 2008 Dec; 72(7):958-65. PubMed ID: 19021282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized, Double-Blind Study Comparing Patient Comfort and Safety Between Iodixanol 320 mg I/mL and Iopamidol 370 mg I/mL in Patients Undergoing Peripheral Arteriography - The COMFORT II Trial.
    Rosenberg C; Martínez-Rodrigo JJ; Lonjedo Vicent E; Macho J; Lim L; Todoran TM;
    J Invasive Cardiol; 2017 Jan; 29(1):9-15. PubMed ID: 28045670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the nephrotoxicity of iodixanol in patients with predisposing factors to contrast medium induced nephropathy referred for contrast enhanced computed tomography.
    Sandstede JJ; Roth A; Machann W; Kaupert C; Hahn D
    Eur J Radiol; 2007 Jul; 63(1):120-3. PubMed ID: 17317065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.